Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05607342 · ClinicalTrials.gov registry record · Early Phase 1
Pilot of Osanetant to Reduce Testosterone in Men With Adenocarcinoma of the Prostate
A Early Phase 1 study, sponsored by University of Kansas Medical Center.
- Terminated
- Registry status
- Early Phase 1
- Development phase
- 1
- Enrollment target
NCT05607342 is a Early Phase 1 study that was terminated before completion, run by University of Kansas Medical Center. The registered enrollment target is 1 participants.
The verdict
NCT05607342, a Early Phase 1 study, was terminated before completion, sponsored by University of Kansas Medical Center.
- TERMINATED
- Registry status
- Early Phase 1
- Development phase
- 1 participants
- Enrollment target
Study Summary
To evaluate the effect of Osanetant on testosterone levels in men with prostate cancer within 28 days of therapy.
Interventions
- DRUG Osanetant
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2023-01-03 |
| Est. Completion | 2023-11-06 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05607342
The ClinicalTrials.gov registry entry for NCT05607342 describes a study currently listed as terminated, categorized as Early Phase 1. The registered enrollment target is 1 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Kansas Medical Center, which has 408 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Osanetant is the first listed.
NCT05607342 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05607342 about?
NCT05607342 is a clinical study titled "Pilot of Osanetant to Reduce Testosterone in Men With Adenocarcinoma of the Prostate". To evaluate the effect of Osanetant on testosterone levels in men with prostate cancer within 28 days of therapy.
What is the current status of trial NCT05607342?
This trial is currently terminated. It is a Early Phase 1 study. The enrollment target is 1 participants. The study started on 2023-01-03. Estimated completion is 2023-11-06.
What interventions are being tested in trial NCT05607342?
The interventions under investigation include: Osanetant (DRUG).
Who is sponsoring clinical trial NCT05607342?
This trial is sponsored by University of Kansas Medical Center, which has 408 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.